Literature DB >> 22818289

Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression.

Silvia D'Ippolito1, Fiorella Di Nicuolo, Riccardo Marana, Roberta Castellani, John Stinson, Chiara Tersigni, Giovanni Scambia, Nicoletta Di Simone.   

Abstract

OBJECTIVE: To examine the effects of low molecular weight heparins (LMWHs) on extravillous trophoblast (EVTC) invasiveness and on EVTC expression/secretion of heparin binding-EGF (HB-EGF) and cystein-rich angiogenic inducer 61 (Cyr61), both of which are involved in the process of EVTC invasion. Furthermore, to investigate the intracellular DNA binding activity of activator protein (AP)-1.
DESIGN: Experimental study.
SETTING: Department of Obstetrics Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy. PATIENT(S): Cultures of primary EVTC cells isolated from patients with first trimester unexplained recurrent miscarriage. INTERVENTION(S): The effects of LMWHs on EVTC invasiveness were examined by an in vitro matrigel invasion assay. Matrix metalloprotease-2 activity (MMP-2) was examined by gelatin zimography. HB-EGF and Cyr61 expression and secretion were studied by Western blot analysis and ELISA assay. AP-1 activity was measured through a multiwell colorimetric assay. MAIN OUTCOME MEASURE(S): The EVTC invasiveness, the expression/secretion of HB-EGF and Cyr61 proteins, and the AP-1 DNA binding activity in the presence of increasing concentrations of LMWHs were investigated. RESULT(S): Both LMWHs, and primarily tinzaparin, increased EVTC invasiveness, by enhancing the MMP-2 proteolytic activity, and induced the expression/secretion of HB-EGF and Cyr61 in EVTC. This effect was mediated by an increased DNA binding activity of AP-1. CONCLUSION(S): Both LMWHs are able to promote EVTC development because they are able to stimulate the EVTC invasive properties. Our results may provide a possible biological rationale for the clinical use of LMWH for placental-mediated pregnancy complications unrelated to prothrombotic disorders.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22818289     DOI: 10.1016/j.fertnstert.2012.06.042

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor.

Authors:  Alan D Bolnick; Jay M Bolnick; Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Omar J Pasalodos; Pankaj K Singhal; Jing Dai; Michael P Diamond; D Randall Armant; Sascha Drewlo
Journal:  Hum Reprod       Date:  2017-06-01       Impact factor: 6.918

2.  Maternal low molecular weight heparin versus sildenafil citrate for fetal growth restriction: a randomized, parallel groups, open-label clinical trial.

Authors:  R Rasheedy; G El Bishry; R Tarek
Journal:  J Perinatol       Date:  2019-11-06       Impact factor: 2.521

3.  Enoxaparin Increases D6 Receptor Expression and Restores Cytoskeleton Organization in Trophoblast Cells from Preeclampsia.

Authors:  Chiara Tersigni; Giuseppe Maulucci; Roberta Castellani; Giada Bianchetti; Marianna Onori; Rita Franco; Greta Barbaro; Marco De Spirito; Antonio Lanzone; Giovanni Scambia; Nicoletta Di Simone
Journal:  Cells       Date:  2022-06-27       Impact factor: 7.666

Review 4.  The physiologic and therapeutic role of heparin in implantation and placentation.

Authors:  Michela Quaranta; Offer Erez; Salvatore Andrea Mastrolia; Arie Koifman; Elad Leron; Tamar Eshkoli; Moshe Mazor; Gershon Holcberg
Journal:  PeerJ       Date:  2015-01-06       Impact factor: 2.984

5.  Altered expression of G1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise.

Authors:  Anna Maria Nuzzo; Domenica Giuffrida; Bianca Masturzo; Paolo Mele; Ettore Piccoli; Carola Eva; Tullia Todros; Alessandro Rolfo
Journal:  Cell Cycle       Date:  2016-12-12       Impact factor: 4.534

6.  The HMGB1/RAGE Pro-Inflammatory Axis in the Human Placenta: Modulating Effect of Low Molecular Weight Heparin.

Authors:  Cristian Zenerino; Anna Maria Nuzzo; Domenica Giuffrida; Marilisa Biolcati; Alessandra Zicari; Tullia Todros; Alessandro Rolfo
Journal:  Molecules       Date:  2017-11-17       Impact factor: 4.411

Review 7.  Preimplantation and postimplantation therapy for the treatment of reproductive failure.

Authors:  Pratap Kumar; Siddharth Mahajan
Journal:  J Hum Reprod Sci       Date:  2013-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.